Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - BioCardia, Inc. | ex_166914.htm |
| EX-32.1 - EXHIBIT 32.1 - BioCardia, Inc. | ex_166913.htm |
| EX-31.2 - EXHIBIT 31.2 - BioCardia, Inc. | ex_166912.htm |
| EX-31.1 - EXHIBIT 31.1 - BioCardia, Inc. | ex_166911.htm |
| EX-21.1 - EXHIBIT 21.1 - BioCardia, Inc. | ex_166908.htm |
| EX-4.10 - EXHIBIT 4.10 - BioCardia, Inc. | ex_179353.htm |
| 10-K - FORM 10-K - BioCardia, Inc. | bcda20191231_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
BioCardia, Inc.:
We consent to the incorporation by reference in the registration statements (No. 333-215968, 333-224368, 333-236405) on Form S-8 and the registration statement (No. 333-218124) on Form S-3 of BioCardia, Inc. of our report dated April 8, 2020, with respect to the consolidated balance sheets of BioCardia, Inc. as of December 31, 2019 and 2018, the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes, which report appears in the December 31, 2019 annual report on Form 10-K of BioCardia, Inc.
Our report dated April 8, 2020 contains an explanatory paragraph that states that the Company has incurred net losses and negative cash flows from operations since its inception and had an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Our report dated April 8, 2020 refers to a change in the method of accounting for leases as of January 1, 2019.
San Francisco, California
April 8, 2020